Amendment reduces and simplifies royalty structure on Teverelix® from ~4% to 2% while preserving global rights and IP control ...
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on ...
The Company enters 2026 with Multiple Phase 2 Catalysts, AI-enabled drug development strategy, and regulatory optionality as ...
For most of modern history, the open ocean has been treated as a place apart. Beyond the 200-nautical-mile limits of national ...
BackFit Health + Spine has accumulated 335 reviews on its Google Business Profile for the Goodyear location, achieving an ...
PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 23, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing ...
Medicus Pharma Ltd. (Nasdaq: MDCX) is a precision guided biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets ...
GSK gets an entry in the list with Exdensur (depemokimab), a twice-yearly injectable IL-5 inhibitor for severe asthma, which ...
Aseptic processing demands reliable, robust, and validated analytical methods to ensure sterility, safety, and quality, ...
Organisations are beginning to implement zero-trust models for data governance thanks to the proliferation of poor quality AI ...
The Infocomm Media Development Authority has released a guide to help enterprises deploy AI agents safely and address ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results